BELLUS Health Inc.
BLU
|
$14.74
0.03%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (2.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (688.59% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 1,869,211,386
http://www.bellushealth.com
Sec Filling | Patents | 40 employees
(CA) BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
chronic cough hypersensitisation treatment
add to watch list Paper trade email alert is off
ChemoCentryx, Inc.
CCXI
|
$51.99
-0.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees
(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
cancer autoimmunity
add to watch list Paper trade email alert is off
Chindata Group Holdings Limited
CD
|
$8.45
1.3%
12M
|
Technology Services
(0.0% 1d) (0.0% 1m) (28.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 1,717,627,723
http://www.chindatagroup.com
Sec Filling | Patents | 1315 employees
(China (Mainland)) Chindata Group Holdings Ltd. operates data centers. It provides carrier-neutral hyperscale data center solutions in Asia-Pacific emerging markets, focusing on the China, India and Southeast Asia markets. The company was founded by Jing Ju in 2015 and is headquartered in Beijing, China.
china
add to watch list Paper trade email alert is off
Citrix Systems, Inc.
CTXS
|
$103.9
0.05%
|
Technology Services
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (130.44% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 13,183,359,916
http://www.citrix.com
Sec Filling | Patents | 8400 employees
Citrix Systems, Inc. engages in the design, development, and marketing of information technology solutions. It provides digital workspace that unifies apps, data, and services. It markets and licenses its products directly to customers through web, systems integrators, value-added resellers, and service providers. The company was founded by Edward E. Iacobucci on April 17, 1989 and is headquartered in Fort Lauderdale, FL.
information technology
add to watch list Paper trade email alert is off
Clovis Oncology, Inc.
CLVS
|
$0.0812
-3.94%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (26.22% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 11,770,367
http://www.clovisoncology.com
Sec Filling | Patents | 484 employees
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
acquisitions cancer prostate cancer liver treatment cancer treatments
Drugs
Rubraca (rucaparib)add to watch list Paper trade email alert is off
Codiak BioSciences, Inc.
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.9% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 2,099,289
http://www.codiakbio.com
Sec Filling | Patents | 105 employees
(United States) Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.
diagnostics
add to watch list Paper trade email alert is off
Blonder Tongue Laboratories, Inc.
BDR
4
|
$0.305
0.0%
|
Electronic Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (1.5% 2d) (3.0% 3d) (0.0% 7d) (192.81% volume)
Earnings Calendar:
Market Cap:
http://www.blondertongue.com
Sec Filling | Patents | 93 employees
Blonder Tongue Laboratories, Inc. operates as a technology development and manufacturing company, which engages in delivering television signal encoding, transcoding, digital transport, and broadband product solutions for applications. It also offers system operators and integrators serving the cable, broadcast, satellite, institutional, and professional video markets with solutions for the provision of content contribution, distribution, and video delivery to homes and businesses. The company was founded by Ben H. Tongue and Isaac S. Blonder in 1950 and is headquartered in Old Bridge, NJ.
satellite msa c-abl
add to watch list Paper trade email alert is off
Bluerock Residential Growth REIT, Inc.
BRG
|
$26.6
0.0%
|
Finance
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (637.99% volume)
Earnings Calendar:
Market Cap: $ 811,478,060
http://www.bluerockresidential.com
Sec Filling | Patents | 2018 employees
(US) Bluerock Residential Growth REIT, Inc. operates as a real estate investment trust. It engages in acquiring apartment properties. Its investment objective is to maximize long term stockholder value by investing in properties that shows substantial growth. The company was founded on July 25, 2008 and is headquartered in New York, NY.
msa
add to watch list Paper trade email alert is off
Kaleyra, Inc.
KLR
|
$7.24
0.0%
110K
|
Communications
(0.0% 1d) (0.0% 1m) (258.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-6.38% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 96,479,661
http://www.kaleyra.com
Sec Filling | Patents | 267 employees
(US) Kaleyra, Inc. is a global group providing mobile communication services for financial institutions and enterprises. The company trough its proprietary platform, it manages multi-channel integrated communication services on a global scale, comprising of messages, push notifications, e-mail, instant messaging, voice services and chatbots. Kaleyra was founded by Dario Leopoldo Calogero in 1999 and is headquartered in Milan, Italy.
communication
add to watch list Paper trade email alert is off
Spark Networks, Inc.
LOV
4
|
$0.212
-8.74%
-9.27%
480K
|
Consumer Services
(0.0% 1d) (0.0% 1m) (-73.3% 1y) (0.0% 2d) (-8.7% 3d) (0.0% 7d) (-55.04% volume)
Earnings Calendar:
Market Cap: $ 55,660,070
http://www.spark.net
Sec Filling | Patents | 2020 employees
(DE) Spark Networks SE operates as a holding company. The firm engages in the operation of online dating sites and applications. It operates through the following segments: North America and International. The North America segment consists of the firm's operations in the United States and Canada. The International segment includes all other operations except for the United States and Canada. The company was founded on April 5, 2017 and is headquartered in Berlin, Germany.
msa
add to watch list Paper trade email alert is off
Activision Blizzard, Inc
ATVI
|
$94.42
0.13%
7.3M
|
Consumer Durables
(0.0% 1d) (0.0% 1m) (10.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (157.69% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 74,289,497,374
http://www.activisionblizzard.com
Sec Filling | Patents | 9200 employees
Activision Blizzard, Inc. engages in the development and publication of interactive entertainment. It operates through the following segments: Activision Publishing, Blizzard Entertainment, and King Digital Entertainment. The Activision Publishing segment develops and publishes interactive software products and entertainment content, particularly for the console platform. The Blizzard Entertainment segment develops and publishes interactive software products and entertainment content, particularly for the PC platform. The King Digital Entertainment segment develops and publishes interactive entertainment content and services, particularly on mobile platforms, such as Google's Android and Apple's iOS. The company was founded in 1979 and is headquartered in Santa Monica, CA.
add to watch list Paper trade email alert is off
Advanced Emissions Solutions, Inc.
ADES
4
|
$3.36
2.38%
100K
|
Producer Manufacturing
(0.0% 1d) (0.0% 1m) (68.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-66.05% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 111,716,892
http://www.adaes.com
Sec Filling | Patents | 133 employees
Advanced Emissions Solutions, Inc. is a holding company, which engages in the provision of environmental and emission control equipment to power generation industry. It operates through the Refined Coal and Power Generation and Industrials segments. The Refined Coal segment includes Tinuum Group, Tinuum Services, and GWN Manager. The Power Generation and Industrials segment refers to the sale of Activated Carbon Injection and Dry Sorbent Injection equipment systems, chemical sales, consulting services, and other sales related to the reduction of emissions in the coal-fired electric generation process and the electric utility industry. The company was founded in 1996 and is headquartered in Highlands Ranch, CO.
injection eletrical
add to watch list Paper trade email alert is off
II-VI Incorporated
IIVI
S
|
$227.08
5.49%
0.0%
0
|
Electronic Technology
(0.0% 1d) (0.0% 1m) (37.0% 1y) (0.0% 2d) (1.9% 3d) (0.0% 7d) (946.44% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 7,105,479,212
http://www.ii-vi.com
Sec Filling | Patents | 22969 employees
II-VI, Inc. engages in the development, refinement, manufacturing, and marketing of engineered materials and opto-electronic components and devices for precision in the field of industrial materials processing, optical communications, aerospace and defense, consumer electronics, semiconductor capital equipment, life sciences, and automotive applications and markets. It operates through the following segments: Photonic Solutions and Compound Semiconductors. The Photonic Solutions segment manufactures crystal materials, optics, microchip lasers and optoelectronic modules for use in optical communication networks and other diverse consumer and commercial applications, pump lasers, optical isolators, and optical amplifiers and micro-optics for optical amplifiers, for both terrestrial and submarine applications within the optical communications market. The Compound Semiconductors segment designs, manufactures and markets optical and electro-optical components and materials, infrared optical components and high-precision optical assemblies for aerospace and defense, medical and commercial laser imaging applications, semiconductor lasers and detectors for optical interconnects and sensing applications, unique engineered materials for thermoelectric and silicon carbide applications servicing the semiconductor, aerospace and defense and medical markets. The company was founded Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.
defense electronics optical optoelectronic automotive semiconductor photo communication
add to watch list Paper trade email alert is off
ImmunoGen, Inc.
IMGN
|
$31.23
0.03%
49M
|
Health Technology
(0.0% 1d) (0.0% 1m) (621.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 8,315,433,277
http://www.immunogen.com
Sec Filling | Patents | 75 employees
(US) ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.
cancer antibody
add to watch list Paper trade email alert is off
IMV Inc.
IMV
|
$0.8225
-2.74%
45K
|
Health Technology
(0.0% 1d) (0.0% 1m) (22.8% 1y) (-2.5% 2d) (-2.5% 3d) (0.0% 7d) (-76.64% volume)
Earnings Calendar: 2023-05-12
Market Cap: $ 9,632,821
http://www.imv-inc.com
Sec Filling | Patents | n/a employees
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.
vaccine covid cancer ovarian cancer immunotherapy infectious disease glass t-cell ceiling
add to watch list Paper trade email alert is off
Infrastructure and Energy Alternatives, Inc.
IEA
|
$13.72
-0.43%
0.0%
|
Industrial Services
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.3% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 667,002,863
http://www.iea.net
Sec Filling | Patents | 3250 employees
Infrastructure & Energy Alternatives, Inc. engages in the provision of infrastructure solutions for the renewable energy, traditional power, and civil infrastructure industries throughout the United States. The firm operates through Renewables and Specialty Civil segments. The Renewables segment operates throughout the United States and specializes in a range of services that include full EPC project delivery, design, site development, construction, installation and restoration of infrastructure services for the wind and solar industries. The Specialty Civil segment operates throughout the United States and specializes in a range of services that include Heavy civil construction, Environmental remediation, and Rail Infrastructure services. The company was founded in 2011 and is headquartered in Indianapolis, IN.
energy solar renewable construction
add to watch list Paper trade email alert is off
IntriCon Corporation
IIN
|
$24.24
0.04%
0.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (40.43% volume)
Earnings Calendar: 2022-08-08
Market Cap:
http://www.intricon.com
Sec Filling | Patents | 780 employees
Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. It operates through the Body-Worn Device and Hearing Health Direct-To-End Consumer segments. The Body-Worn Device segment comprises medical, hearing health, and professional audio markets. The Hearing Health Direct-To-End Consumer segment provides advanced hearing products such as ultra-miniature volume controls and trimmers, custom amplifiers, and custom, completed hearing instruments. The company was founded in 1930 and is headquartered in Arden Hills, MN.
audio
add to watch list Paper trade email alert is off
InVivo Therapeutics Holdings Corp.
NVIV
|
$0.3207
-25.16%
1.9M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-60.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-98.2% volume)
Earnings Calendar:
Market Cap: $ 995,917
http://www.invivotherapeutics.com
Sec Filling | Patents | 6 employees
(US) Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.
spinal cord msa treatment
add to watch list Paper trade email alert is off
Genocea Biosciences, Inc.
GNCA
|
$0.051
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-15.0% 3d) (0.0% 7d) (-35.74% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.genocea.com
Sec Filling | Patents | 59 employees
(US) Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
vaccine cancer immunotherapy t-cell genetic treatment ceiling
add to watch list Paper trade email alert is off
Global Blood Therapeutics, Inc.
GBT
|
$68.49
0.02%
-0.02%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (73.96% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 4,621,443,500
http://www.gbt.com
Sec Filling | Patents | 352 employees
(US) Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
t-cell ceiling
Drugs
OXBRYTA (Voxelotor)add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Last 48 Hours Insiders Buying
IZEA | $2.5 -2.4% 8.6K
|
Technology Services
|
00:00
RKT P 383 | $11.38 -0.52% 1.05% 1.4M
|
Finance
|
22:30
CTRN P 18090 | $22.46 -1.01% -1.02% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.795 2.38% 0.18% 35K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.14 -0.16% -0.16% 3.1M
|
Health Technology
|
16:30
RMCF | $3.51 -3.7% -3.85% 3.8K
|
Consumer Non-Durables
|
20:10